Last reviewed · How we verify
Placebo-matching Ubrogepant
Placebo-matching Ubrogepant is a Calcitonin gene-related peptide receptor antagonist Small molecule drug developed by Allergan. It is currently in Phase 3 development for Acute treatment of migraine attacks with or without aura, Prevention of migraine attacks.
Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
Ubrogepant is a calcitonin gene-related peptide receptor antagonist. Used for Acute treatment of migraine attacks with or without aura, Prevention of migraine attacks.
At a glance
| Generic name | Placebo-matching Ubrogepant |
|---|---|
| Sponsor | Allergan |
| Drug class | Calcitonin gene-related peptide receptor antagonist |
| Target | Calcitonin gene-related peptide receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals in the brain. This leads to a reduction in the frequency and severity of migraine attacks.
Approved indications
- Acute treatment of migraine attacks with or without aura
- Prevention of migraine attacks
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (PHASE3)
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine (PHASE3)
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (PHASE3)
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) (PHASE2)
- Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (PHASE3)
- A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-matching Ubrogepant CI brief — competitive landscape report
- Placebo-matching Ubrogepant updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Placebo-matching Ubrogepant
What is Placebo-matching Ubrogepant?
How does Placebo-matching Ubrogepant work?
What is Placebo-matching Ubrogepant used for?
Who makes Placebo-matching Ubrogepant?
What drug class is Placebo-matching Ubrogepant in?
What development phase is Placebo-matching Ubrogepant in?
What are the side effects of Placebo-matching Ubrogepant?
What does Placebo-matching Ubrogepant target?
Related
- Drug class: All Calcitonin gene-related peptide receptor antagonist drugs
- Target: All drugs targeting Calcitonin gene-related peptide receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute treatment of migraine attacks with or without aura
- Indication: Drugs for Prevention of migraine attacks
- Compare: Placebo-matching Ubrogepant vs similar drugs
- Pricing: Placebo-matching Ubrogepant cost, discount & access